Alumis Inc. Common Stock (ALMS) Stock Price

ALMSStock
$23.96+375.83%52W
Market Cap$3.10B
P/E
PEG Ratio
Div yield
Beta0.72

ALMS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-27.53%
Price vs S&P 500 (4W)-17.85%
VGM Score41.43

ALMS Earnings Surprise History

Q2 25-1.47est. -1.39
Q3 25-1.06est. -1.00
Q4 25-0.25est. -0.98
Q1 26-0.74est. -0.83
Q2 26-0.79est. -0.71

ALMS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.41
4.35
4.35
4.38

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ALMSAlumis Inc. Common Stock
FB$23.96
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Alumis Inc. Common Stock

Alumis Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for autoimmune disorders. Leveraging its proprietary precision data analytics platform, the company aims to replace broad immunosuppression with more specific therapeutic approaches. Its pipeline includes drug candidates targeting TYK2 and IRF5 pathways.